Protocolo de tratamiento en urgencias del paciente con síndrome coronario agudo con elevación del segmento ST

  1. García Sebastián, C. 1
  2. Abellas Sequeiros, M. 1
  3. Monteagudo Ruiz, J.M. 1
  4. Zamorano Gómez, J.L. 1
  1. 1 Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades cardiovasculares (IV)

Serie: 13

Número: 38

Páginas: 2203-2206

Tipo: Artículo

DOI: 10.1016/J.MED.2021.07.006 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

Acute coronary syndrome (ACS) is a major cause of mortality. It is essential to identify patients with ST-segment elevation (STSE ACS). These patients have an increased risk of complications and fast and structured action in the emergency department is fundamental. The initial measures included checking haemodynamic stability, performing an electrocardiogram, monitoring the patient, and ensuring the availability of a defibrillator. STSE ACS is treated medically and by revascularisation. The initial objective of medical treatment is symptom control and dual antiplatelet therapy with ASA and a P2Y12 inhibitor, preferably prasugrel or ticagrelor. There are two revascularisation techniques: primary angioplasty (of choice if available in under 120 minutes) or fibrinolysis.

Referencias bibliográficas

  • Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR. Fourth universal definition of myocardial infarction (2018). Rev Esp Cardiol. 2019;72(1):72.e1-e27.
  • Ibáñez B, James S, Agewall S, Antunes MJ, Bucciarelli Ducci C, Bueno H. ESC Scientific Document Group. 2017 ESC Guide-lines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77.
  • O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61(4):e78-e140.
  • Cabello JB, Burls A, Emparanza JI, Bayliss S, Quinn T. Oxygen therapy for acute myocardial infarction. Cochrane Database Syst Rev 2013;8:CD007160.
  • Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15.
  • Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57.
  • Marzal Martín D, López Sendón Henschel JL, Rodríguez Padial L. Proceso asistencial simplificado del síndrome coronario agudo. Madrid: Sociedad Española de Cardiología; 2016.
  • Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351): 13-20.
  • Van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G. ASSENT-2 Investigators, Assessment of the safety and efficacy of a new thrombolytic. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J. 2001;22(24):2253-61.
Fuente de los datos: Dialnet